Skip to content
OpenCapital
Get started

Aclaris Therapeutics ACRS Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$2.0MBeat by $674.3K
EPS-$0.15Beat by $0.01
Revenue estimate$1.3M
EPS estimate-$0.16

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$1.4M
EPS estimate-$0.16

Financials

Q1 2026

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$749.99M+312%
Enterprise value$723.32M+355%
P/S89.6×+78.8×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Segments

By product

See full
Dermatology Therapeutics$1.5M—
Contract Research$537.0K—

By segment

See full
Single Reportable$2.0M—

Versus estimates

Revenue

Q1 2026$2.0MBeat by $674.3K
Q4 2025$1.3MMiss by $776.1KQ3 2025$3.3MBeat by $1.2MQ2 2025$1.8MBeat by $639.5KQ1 2025$1.5MMiss by $2.1MQ4 2024$9.2MBeat by $2.2M

Diluted EPS

Q1 2026-$0.15Beat by $0.01
Q4 2025-$0.16Miss by $0.01Q3 2025-$0.12Beat by $0.01Q2 2025-$0.13In lineQ1 2025-$0.12Beat by $0.05Q4 2024-$0.10Miss by $0.01

Ask the moment Aclaris Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aclaris Therapeutics report Q1 2026 earnings?
Aclaris Therapeutics (ACRS) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Aclaris Therapeutics's Q1 2026 revenue and EPS?
Aclaris Therapeutics reported revenue of $2.0M and eps of $-0.15 for Q1 2026.
Did Aclaris Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $1.3M by $674.3K. EPS beat the consensus estimate of $-0.16 by $0.01.
How did Aclaris Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 37.2% from $1.5M a year earlier and eps declined 25.0% from $-0.12.
Where can I find Aclaris Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-056669) and the 10-Q periodic report (0001104659-26-057202) directly on SEC EDGAR. The filing index links above go to sec.gov.